Atabecestat (C007B-326324)

Atabecestat (JNJ-54861911) is a potent brain-penetrant and orally active β-site amyloid precursor protein cleaving enzyme 1 (BACE1) inhibitor, achieves robust and high CSF Aβ reduction. Atabecestat s tolerated and displays a sustained pharmacokinetic (PK) and pharmacodynamic (PD) characteristics. Atabecestat has the potential for Alzheimer's Disease treatmentIn VivoAtabecestat (100 and 300 mg/kg; p.o. once daily for 3 days) reduces the human Aβ levels in mice. Atabecestat (300 mg/kg; p.o. once) inhibits the exacerbation of vascular abnormalities in APPPS1 mice with 3D6 treatment. MCE has not independently confirmed the accuracy of these methods. They are for reference only. Animal Model: 5-week-old APPPS1 miceDosage: 100 and 300 mg/kg Administration: Oral gavage; 100 and 300 mg/kg; once daily for 3 days Result: Reduced the level of human Aβ 1-40 and Aβ 1-42 levels in the brain of APPPS1 mice at a dose of 300 mg/kg and resulted in less reduction of human Aβ levels at 24 h with a dose of 100 mg/kg.IC50& Target:BACE1. Specification: 10mM in DMSO Molecular Formula: C18H14FN5OS Molecular Weight: 367.4

UPC:

51143004

Condition:

New

Weight:

1.06 Ounces

HazmatClass:

No

Quantity:

1

Unit of Measurement:

EA

WeightUOM:

LB

MPN:

A655608-1ml

CAS:

1200493-78-2

Product Size:

1ml